BCL2 and acute myeloid leukemia: These results are consistent with previously reported data indicating limited anti-AML activity of BCL-2 inhibitors when used as monotherapy, underscoring the importance of combination therapy for AML, particularly in the relapsed and refractory settings [13,14,15].